A Clinical Trial of Antiplatelets in Psoriasis (NCT07744191) | Clinical Trial Compass
Not Yet RecruitingPhase 4
A Clinical Trial of Antiplatelets in Psoriasis
United States60 participantsStarted 2026-09
Plain-language summary
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. One of the following:
. A history of psoriasis as confirmed by a board-certified dermatologist OR
. A history of psoriatic arthritis as confirmed by a board-certified rheumatologist
. Age ≥ 18 \& \< 90 years
. Able and willing to provide written informed consent for the study
. English-speaking unless a translated informed consent form is approved
. No previous antiplatelet or anticoagulant use for 14 days prior to enrollment
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing antiplatelet medications in people with psoriasis and psoriatic arthritis — can you explain what role platelets might play in my condition and why targeting them could be relevant to my care?
2The trial is measuring changes in 'endothelial pro-inflammatory transcript expression,' which seems to be about inflammation in blood vessel walls — does that mean this study is focused more on my cardiovascular risk from psoriasis than on improving my skin or joint symptoms directly?
3Since this trial is Phase 4, does that mean the antiplatelet drugs being studied are already approved and used for other conditions, and what does that tell us about what's already known about their safety profile?
4The trial isn't recruiting yet — given that timeline uncertainty, would it make sense for me to start a standard psoriasis or psoriatic arthritis treatment now, and could that affect whether I'd even be eligible later?
5Are there already established treatments for my psoriasis or psoriatic arthritis that address cardiovascular inflammation risk, and how would you weigh those options against waiting to potentially join this trial?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mean change in the composite endothelial pro-inflammatory transcript expression
Timeframe: Baseline, Follow-up Visit 1 (Week 4)
2
Mean change in the composite endothelial pro-inflammatory transcript expression
Timeframe: Baseline, Follow-up Visit 3 (Week 12)
3
Mean change in the composite endothelial pro-inflammatory transcript expression